Correlation Between TSS, Common and Rafarma Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both TSS, Common and Rafarma Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining TSS, Common and Rafarma Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between TSS, Common Stock and Rafarma Pharmaceuticals, you can compare the effects of market volatilities on TSS, Common and Rafarma Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in TSS, Common with a short position of Rafarma Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of TSS, Common and Rafarma Pharmaceuticals.

Diversification Opportunities for TSS, Common and Rafarma Pharmaceuticals

0.66

Correlation Coefficient

TSS, Common  Rafarma Pharmaceuticals

Poor diversification

The 3 months correlation between TSS, and Rafarma is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding TSS, Common Stock and Rafarma Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rafarma Pharmaceuticals and TSS, Common is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on TSS, Common Stock are associated (or correlated) with Rafarma Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rafarma Pharmaceuticals has no effect on the direction of TSS, Common i.e., TSS, Common and Rafarma Pharmaceuticals go up and down completely randomly.

Pair Corralation between TSS, Common and Rafarma Pharmaceuticals

Given the investment horizon of 90 days TSS, Common is expected to generate 1.56 times less return on investment than Rafarma Pharmaceuticals. But when comparing it to its historical volatility, TSS, Common Stock is 1.91 times less risky than Rafarma Pharmaceuticals. It trades about 0.14 of its potential returns per unit of risk. Rafarma Pharmaceuticals is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  3.80  in Rafarma Pharmaceuticals on September 17, 2024 and sell it today you would earn a total of  2.30  from holding Rafarma Pharmaceuticals or generate 60.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	98.46%
Values	Daily Returns

TSS, Common Stock  vs.  Rafarma Pharmaceuticals

TSS, Common Stock

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in TSS, Common Stock are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite fairly abnormal basic indicators, TSS, Common demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Rafarma Pharmaceuticals

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Rafarma Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat fragile technical and fundamental indicators, Rafarma Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with TSS, Common and Rafarma Pharmaceuticals

The main advantage of trading using opposite TSS, Common and Rafarma Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if TSS, Common position performs unexpectedly, Rafarma Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rafarma Pharmaceuticals will offset losses from the drop in Rafarma Pharmaceuticals' long position.

The idea behind TSS, Common Stock and Rafarma Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.